生物标志物的风险
Biomarker Jeopardy.
作者信息
Kurtin Sandra E, Henglefelt Alyssa, Price Allyson
机构信息
The University of Arizona Cancer Center, Tucson, Arizona.
HonorHealth Virginia G. Piper Cancer Care Network, Scottsdale, Arizona.
出版信息
J Adv Pract Oncol. 2021 Apr;12(3):285-288. doi: 10.6004/jadpro.2021.12.3.13. Epub 2021 Apr 1.
Abstract
The popular Biomarker Jeopardy session returned this year at JADPRO Live 2020. Sandra E. Kurtin, PhD, ANP-C, AOCN®, led the session, and was joined by Alyssa Henglefelt, PharmD, BCOP, and Allyson Price, PA-C. Using a Jeopardy format, they identified specific biomarkers while discussing targeted therapies and class effects APs should be aware of.
摘要
广受欢迎的生物标志物问答环节今年在2020年JADPRO直播大会上再度回归。医学博士、认证成人护理执业医师、肿瘤护理认证专家桑德拉·E·库尔廷主持了该环节，药剂学博士、肿瘤药学认证专家艾丽莎·亨格尔费尔特以及助理医师认证专家艾莉森·普赖斯也一同参与。他们采用问答竞赛的形式，在讨论靶向治疗以及高级实践提供者（AP）应了解的类别效应的同时，确定了特定的生物标志物。
相似文献
1
Biomarker Jeopardy.生物标志物的风险
J Adv Pract Oncol. 2021 Apr;12(3):285-288. doi: 10.6004/jadpro.2021.12.3.13. Epub 2021 Apr 1.
2
Biomarker Jeopardy.生物标志物的风险
J Adv Pract Oncol. 2022 Apr;13(3):292-297. doi: 10.6004/jadpro.2022.13.3.22. Epub 2022 May 23.
3
Optimizing Treatment of Chronic Lymphocytic Leukemia.优化慢性淋巴细胞白血病的治疗
J Adv Pract Oncol. 2021 Apr;12(3):325-328. doi: 10.6004/jadpro.2021.12.3.23. Epub 2021 Apr 1.
4
Cardio-Oncology: The Intersection Between Cardiovascular Disease and Cancer.心脏肿瘤学：心血管疾病与癌症的交叉领域
J Adv Pract Oncol. 2021 Apr;12(3):253-256. doi: 10.6004/jadpro.2021.12.3.6. Epub 2021 Apr 1.
5
Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia.风险评估与风险适应性治疗选择：慢性淋巴细胞白血病的病例分析方法
J Adv Pract Oncol. 2017 Jul-Aug;8(5):502-520. Epub 2017 Jul 1.
6
Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma.将新兴数据整合到临床实践中：一种针对多发性骨髓瘤的基于病例的方法。
J Adv Pract Oncol. 2017 May-Jun;8(4):365-377. Epub 2017 May 1.
7
Use of Diagnostic Tests in Advanced Non-Small Cell Lung Cancer.诊断测试在晚期非小细胞肺癌中的应用
J Adv Pract Oncol. 2017 Mar;8(2):173-185. doi: 10.6004/jadpro.2017.8.2.5. Epub 2017 Mar 1.
8
2022-2023 Drug Updates: Investigational Therapeutics in the Pipeline.2022 - 2023药物更新：正在研发中的试验性疗法
J Adv Pract Oncol. 2024 Apr;15(3):182-185. doi: 10.6004/jadpro.2024.15.3.5. Epub 2024 Apr 1.
9
Diagnosis and Treatment of AL and ATTR Amyloidosis.AL型和ATTR型淀粉样变性的诊断与治疗
J Adv Pract Oncol. 2021 Apr;12(3):329-332. doi: 10.6004/jadpro.2021.12.3.24. Epub 2021 Apr 1.
10
Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer.棘手问题：抗血小板药物使用者需要了解的关于抗凝剂和癌症患者的知识
J Adv Pract Oncol. 2021 Apr;12(3):262-265. doi: 10.6004/jadpro.2021.12.3.8. Epub 2021 Apr 1.
本文引用的文献
1
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.口服阿扎胞苷维持治疗急性髓系白血病缓解后。
N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.
2
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.塔西美替尼治疗复发或难治性滤泡性淋巴瘤患者的疗效：一项开放标签、单臂、多中心、2 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6.
3
Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.卡马替尼治疗外显子 14 突变或扩增的非小细胞肺癌。
N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787.
4
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.TROPiCS-02 研究：一项评估 sacituzumab govitecan 治疗激素受体阳性/人表皮生长因子受体 2 阴性转移性乳腺癌的 III 期研究。
Future Oncol. 2020 Apr;16(12):705-715. doi: 10.2217/fon-2020-0163. Epub 2020 Mar 30.
5
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
6
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.芦可替尼治疗低危骨髓增生异常综合征患者的疗效。
N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.
7
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.实体瘤中选择性 FGFR 抑制剂的现状与新希望。
Clin Cancer Res. 2020 Feb 15;26(4):764-774. doi: 10.1158/1078-0432.CCR-19-2035. Epub 2019 Oct 4.
8
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
9
Targeting Trop-2 in solid tumors: future prospects.靶向实体瘤中的Trop-2：未来前景
Onco Targets Ther. 2019 Mar 1;12:1781-1790. doi: 10.2147/OTT.S162447. eCollection 2019.
Zotero 插件